New drug trial aims to tackle diabetes in cystic fibrosis patients

NCT ID NCT06995651

Recruiting now Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called dorzagliatin in 15 adults with cystic fibrosis who have trouble controlling their blood sugar. Participants take the drug or a placebo for 7 days each, in a crossover design. The goal is to see if dorzagliatin improves glucose tolerance and insulin secretion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dorzagliatin
What this could lead to: If it works, this could point toward a new treatment for cystic fibrosis-related diabetes by improving how the body handles sugar.
What could go wrong: This is a very early phase 1 trial with only 15 people, so results may not apply to everyone. The drug may not improve glucose tolerance or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS RELATED DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis cystic fibrosis-related diabetes exocrine pancreatic insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS RELATED DIABETES PANCREATIC INSUFFICIENCY

Contacts and locations

Locations

Hospital of University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Pennsylvania Center for Human Phenomic Science (CHPS)
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.